Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 May, 2022 23:49 IST
Alembic Pharmaceuticals gets USFDA nod for Selexipag Tablets
Source: IRIS | 08 Dec, 2021, 06.24PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Alembic Pharmaceuticals (Alembic), a vertically integrated research and development pharmaceutical company, on December 08 announced that the Company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Uptravi Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 nicg, and 1,600 mcg, of Actelion Pharmaceuticals (Actelion).

Selexipag Tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization for PAH.
Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg have an estimated market size of USD 461 million for twelve months ending September 2021 according to IQVIA.

Alembic has received year to date (YTD) 15 approvals (11 final approvals and 4 tentative approvals) and a cumulative total of 154 ANDA 'approvals (134 final approvals arid 20 tentative approvals) from USFDA.

Shares of the company gained Rs 21.60, or 2.73%, to settle at Rs 813.05.  The total volume of shares traded was 56,560 at the BSE (Wednesday).

 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer